| Quarter | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | 19 | 13 | 15 | 12 | 34 | 24 | 31 | 26 | 50 | 34 | 47 | |
Growth YoY Revenue Growth YoY% | -24.6 | 126.1 | 52.2 | 66.8 | 77.8 | 79.5 | 102.8 | 117.3 | 46.9 | 42.8 | 50.2 | |
| 6 | 17 | 11 | 11 | 8 | 25 | 18 | 24 | 21 | 39 | 25 | 36 | |
| 1 | 2 | 2 | 4 | 4 | 9 | 5 | 7 | 5 | 11 | 9 | 11 | |
OPM OPM% | 20.0 | 12.3 | 18.9 | 26.2 | 34.5 | 25.1 | 21.9 | 21.9 | 19.8 | 22.0 | 25.2 | 24.0 |
| 0 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 5 | 2 | 1 | 1 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 |
Depreciation DepreciationCr | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 1 | 2 | 1 | 2 | 2 |
PBT PBTCr | 1 | 3 | 3 | 4 | 3 | 6 | 4 | 7 | 6 | 11 | 7 | 9 |
| 0 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 4 | 2 | 2 | |
| 1 | 2 | 2 | 3 | 3 | 6 | 3 | 5 | 5 | 7 | 5 | 7 | |
Growth YoY PAT Growth YoY% | -48.0 | -18.2 | 14.3 | 143.8 | 279.0 | 73.8 | 81.1 | 81.6 | 10.8 | 82.4 | 29.7 | |
NPM NPM% | 14.8 | 8.5 | 12.2 | 18.2 | 21.6 | 18.1 | 11.8 | 16.2 | 18.1 | 13.6 | 15.0 | 14.0 |
| 0.9 | 1.4 | 2.0 | 2.7 | 2.4 | 6.2 | 2.7 | 4.3 | 3.7 | 5.8 | 4.3 | 5.7 |
| Quarter | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7 | 19 | 13 | 15 | 12 | 34 | 24 | 31 | 26 | 50 | 34 | 47 | |
Growth YoY Revenue Growth YoY% | -24.6 | 126.1 | 52.2 | 66.8 | 77.8 | 79.5 | 102.8 | 117.3 | 46.9 | 42.8 | 50.2 | |
| 6 | 17 | 11 | 11 | 8 | 25 | 18 | 24 | 21 | 39 | 25 | 36 | |
| 1 | 2 | 2 | 4 | 4 | 9 | 5 | 7 | 5 | 11 | 9 | 11 | |
OPM OPM% | 20.0 | 12.3 | 18.9 | 26.2 | 34.5 | 25.1 | 21.9 | 21.9 | 19.8 | 22.0 | 25.2 | 24.0 |
| 0 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 5 | 2 | 1 | 1 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 2 |
Depreciation DepreciationCr | 0 | 0 | 1 | 0 | 1 | 3 | 1 | 1 | 2 | 1 | 2 | 2 |
PBT PBTCr | 1 | 3 | 3 | 4 | 3 | 6 | 4 | 7 | 6 | 11 | 7 | 9 |
| 0 | 1 | 1 | 1 | 1 | 0 | 1 | 2 | 1 | 4 | 2 | 2 | |
| 1 | 2 | 2 | 3 | 3 | 6 | 3 | 5 | 5 | 7 | 5 | 7 | |
Growth YoY PAT Growth YoY% | -48.0 | -18.2 | 14.3 | 143.8 | 279.0 | 73.8 | 81.1 | 81.6 | 10.8 | 82.4 | 29.7 | |
NPM NPM% | 14.8 | 8.5 | 12.2 | 18.2 | 21.6 | 18.1 | 11.8 | 16.2 | 18.1 | 13.6 | 15.0 | 14.0 |
| 0.9 | 1.4 | 2.0 | 2.7 | 2.4 | 6.2 | 2.7 | 4.3 | 3.7 | 5.8 | 4.3 | 5.7 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
Revenue RevenueCr | 22 | 32 | 45 | 87 | 129 | 156 |
Growth Revenue Growth% | 45.6 | 40.8 | 94.9 | 48.4 | 55.2 | |
| 19 | 25 | 36 | 72 | 101 | 121 | |
| 3 | 6 | 8 | 15 | 28 | 36 | |
OPM OPM% | 12.4 | 19.7 | 18.4 | 17.1 | 21.8 | 22.9 |
| 1 | 1 | 2 | 8 | 10 | 8 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 1 | 4 | 5 | 5 |
Depreciation DepreciationCr | 0 | 0 | 1 | 5 | 6 | 7 |
PBT PBTCr | 3 | 7 | 9 | 14 | 27 | 32 |
| -1 | 1 | 3 | 3 | 8 | 9 | |
PAT PATCr | 4 | 6 | 6 | 10 | 19 | 23 |
Growth PAT Growth% | 52.5 | -1.3 | 76.7 | 84.1 | 39.5 | |
NPM NPM% | 18.1 | 19.0 | 13.3 | 12.1 | 15.0 | 14.8 |
| 6.9 | 6.2 | 5.5 | 10.2 | 16.3 | 19.4 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|
Revenue RevenueCr | 22 | 32 | 45 | 87 | 129 | 156 |
Growth Revenue Growth% | 45.6 | 40.8 | 94.9 | 48.4 | 55.2 | |
| 19 | 25 | 36 | 72 | 101 | 121 | |
| 3 | 6 | 8 | 15 | 28 | 36 | |
OPM OPM% | 12.4 | 19.7 | 18.4 | 17.1 | 21.8 | 22.9 |
| 1 | 1 | 2 | 8 | 10 | 8 | |
Interest Expense Interest ExpenseCr | 0 | 0 | 1 | 4 | 5 | 5 |
Depreciation DepreciationCr | 0 | 0 | 1 | 5 | 6 | 7 |
PBT PBTCr | 3 | 7 | 9 | 14 | 27 | 32 |
| -1 | 1 | 3 | 3 | 8 | 9 | |
PAT PATCr | 4 | 6 | 6 | 10 | 19 | 23 |
Growth PAT Growth% | 52.5 | -1.3 | 76.7 | 84.1 | 39.5 | |
NPM NPM% | 18.1 | 19.0 | 13.3 | 12.1 | 15.0 | 14.8 |
| 6.9 | 6.2 | 5.5 | 10.2 | 16.3 | 19.4 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
Equity Capital Equity CapitalCr | 8 | 12 | 12 | 12 | 12 | 12 |
Reserves ReservesCr | -3 | 34 | 40 | 53 | 85 | 102 |
| 8 | 12 | 20 | 54 | 88 | 62 | |
| 1 | 4 | 13 | 33 | 41 | 69 | |
| 14 | 63 | 87 | 156 | 237 | 253 | |
| 11 | 49 | 52 | 90 | 140 | 139 | |
| 3 | 13 | 35 | 66 | 97 | 114 | |
| 14 | 63 | 87 | 156 | 237 | 253 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|
Equity Capital Equity CapitalCr | 8 | 12 | 12 | 12 | 12 | 12 |
Reserves ReservesCr | -3 | 34 | 40 | 53 | 85 | 102 |
| 8 | 12 | 20 | 54 | 88 | 62 | |
| 1 | 4 | 13 | 33 | 41 | 69 | |
| 14 | 63 | 87 | 156 | 237 | 253 | |
| 11 | 49 | 52 | 90 | 140 | 139 | |
| 3 | 13 | 35 | 66 | 97 | 114 | |
| 14 | 63 | 87 | 156 | 237 | 253 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| 0 | -19 | 2 | -4 | 5 | |
| 0 | -10 | -20 | -14 | -37 | |
| 1 | 42 | 11 | 14 | 34 | |
Net Cash Flow Net Cash FlowCr | 0 | 14 | -7 | -4 | 2 |
Free Cash Flow Free Cash FlowCr | -1 | -26 | -16 | -15 | -29 |
CFO To PAT CFO To PAT% | -5.4 | -315.7 | 37.5 | -38.0 | 24.3 |
CFO To EBITDA CFO To EBITDA% | -7.9 | -304.0 | 27.2 | -26.8 | 16.7 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| 0 | -19 | 2 | -4 | 5 | |
| 0 | -10 | -20 | -14 | -37 | |
| 1 | 42 | 11 | 14 | 34 | |
Net Cash Flow Net Cash FlowCr | 0 | 14 | -7 | -4 | 2 |
Free Cash Flow Free Cash FlowCr | -1 | -26 | -16 | -15 | -29 |
CFO To PAT CFO To PAT% | -5.4 | -315.7 | 37.5 | -38.0 | 24.3 |
CFO To EBITDA CFO To EBITDA% | -7.9 | -304.0 | 27.2 | -26.8 | 16.7 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 183 | 188 | 296 | 320 | 486 | |
Price To Earnings Price To Earnings | 30.4 | 29.7 | 25.1 | 16.8 | 20.9 | |
Price To Sales Price To Sales | 5.8 | 4.2 | 3.4 | 2.5 | 3.1 | |
Price To Book Price To Book | 4.0 | 3.6 | 4.6 | 3.3 | 4.3 | |
EV To EBITDA EV To EBITDA | 28.3 | 24.4 | 23.4 | 13.8 | 15.9 | |
GPM GPM% | 22.5 | 28.7 | 28.1 | 39.9 | 36.0 | 36.0 |
OPM OPM% | 12.4 | 19.7 | 18.4 | 17.1 | 21.8 | 22.9 |
NPM NPM% | 18.1 | 19.0 | 13.3 | 12.1 | 15.0 | 14.8 |
ROCE ROCE% | 43.0 | 13.2 | 13.2 | 14.8 | 19.1 | 18.1 |
ROE ROE% | 82.7 | 13.2 | 11.4 | 16.3 | 20.0 | 20.3 |
ROA ROA% | 28.5 | 9.6 | 6.8 | 6.7 | 8.2 | 9.1 |
| Financial Year | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Current |
|---|---|---|---|---|---|---|
Market Cap Market CapitalizationCr | 183 | 188 | 296 | 320 | 486 | |
Price To Earnings Price To Earnings | 30.4 | 29.7 | 25.1 | 16.8 | 20.9 | |
Price To Sales Price To Sales | 5.8 | 4.2 | 3.4 | 2.5 | 3.1 | |
Price To Book Price To Book | 4.0 | 3.6 | 4.6 | 3.3 | 4.3 | |
EV To EBITDA EV To EBITDA | 28.3 | 24.4 | 23.4 | 13.8 | 15.9 | |
GPM GPM% | 22.5 | 28.7 | 28.1 | 39.9 | 36.0 | 36.0 |
OPM OPM% | 12.4 | 19.7 | 18.4 | 17.1 | 21.8 | 22.9 |
NPM NPM% | 18.1 | 19.0 | 13.3 | 12.1 | 15.0 | 14.8 |
ROCE ROCE% | 43.0 | 13.2 | 13.2 | 14.8 | 19.1 | 18.1 |
ROE ROE% | 82.7 | 13.2 | 11.4 | 16.3 | 20.0 | 20.3 |
ROA ROA% | 28.5 | 9.6 | 6.8 | 6.7 | 8.2 | 9.1 |
| Market CapitalizationMkt CapCr | 793 | 782 | 660 | 486 | 435 | 402 | 338 |
| Close PriceClose₹ | 147.80 | 223.81 | 285.00 | 406.05 | 762.60 | 285.90 | 93.41 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 278.87 | 32.16 | 29.26 | 20.89 | 15.14 | 32.16 | |
| Price To SalesPS | 1.92 | 3.28 | 3.99 | 3.11 | 1.15 | 1.91 | 2.32 |
| RevenueRevenueCr | 414 | 239 | 165 | 156 | 378 | 210 | 145 |
| Revenue Growth TTMRev Gr TTM% | 13.1% | 13.9% | 55.2% | 19.7% | 27.5% | 6.1% | |
| PAT Growth TTMPAT Gr TTM% | -68.6% | -13.6% | 39.5% | 290.6% | 41.9% | -294.4% |
| Market CapitalizationMkt CapCr | 793 | 782 | 660 | 486 | 435 | 402 | 338 |
| Close PriceClose₹ | 147.80 | 223.81 | 285.00 | 406.05 | 762.60 | 285.90 | 93.41 |
| IndustryIndustry | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations | Pharma Formulations |
| Price To EarningsPE | 278.87 | 32.16 | 29.26 | 20.89 | 15.14 | 32.16 | |
| Price To SalesPS | 1.92 | 3.28 | 3.99 | 3.11 | 1.15 | 1.91 | 2.32 |
| RevenueRevenueCr | 414 | 239 | 165 | 156 | 378 | 210 | 145 |
| Revenue Growth TTMRev Gr TTM% | 13.1% | 13.9% | 55.2% | 19.7% | 27.5% | 6.1% | |
| PAT Growth TTMPAT Gr TTM% | -68.6% | -13.6% | 39.5% | 290.6% | 41.9% | -294.4% |